BHRB vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BHRB presents a stark contrast between deep value and deteriorating fundamental health. While the stock trades significantly below its Graham Number ($98.78) and Intrinsic Value ($227.74) with a low P/E of 8.35, the Piotroski F-Score of 3/9 indicates weak financial health. Strong earnings growth (51.8% YoY) and a consistent track record of beating estimates are offset by a bearish technical trend and a lack of dividend support. The valuation is highly attractive, but the low health score necessitates a cautious approach.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
BHRB vs JPM: Head-to-Head Comparison
This page compares Burke & Herbert Financial Services Corp. (BHRB) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.